迪卡斯系统公司(Delcath Systems, Inc.)近日宣布,其Chemosat美法仑肝脏给药系统已被正式纳入ESMO-EURACAN葡萄膜黑色素瘤临床实践指南,成为肝脏导向区域治疗的推荐选择方案。这一重要认可标志着该创新疗法在专业医疗指南中的地位获得权威确认。
迪卡斯系统公司(Delcath Systems, Inc.)近日宣布,其Chemosat美法仑肝脏给药系统已被正式纳入ESMO-EURACAN葡萄膜黑色素瘤临床实践指南,成为肝脏导向区域治疗的推荐选择方案。这一重要认可标志着该创新疗法在专业医疗指南中的地位获得权威确认。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.